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Ticlopidine prevents renal disease progression in rats with
reduced renal mass
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Ticlopidine prevents renal disease progression in rats with reduced
renal mass. Functional and morphological studies were done in three
groups of male Sprague-Dawley rats after removal of the right kidney
and infarction of approximately five-sixths of the left. Group 1 received
no specific therapy. Group 2 was treated with ticlopidine, 150 mg/kg per
Os, for 50 days starting 10 days after surgical ablation. Group 3 was
given the thromboxane antagonist, GR 32191, 3 mg/kg b.i.d. orally for
50 days, like ticlopidine. Untreated Group 1 rats developed renal
insufficiency, systemic hypertension, progressive proteinuria and gb-
merulosclerosis. In Group 2 treatment with ticlopidine was associated
with less severe impairment of renal function. Proteinuria was signifi-
cantly lower and animals were partially protected from the development
of glomeruloscierosis. These animals had significantly prolonged skin
bleeding time. In vitro ADP and arachidonic acid (AA)-induced platelet
aggregation was inhibited. Systemic blood pressure was significantly
lower than in controls. In Group 3 rats GR 32191 failed to influence
progressive proteinuria and severity of glomeruloscierosis which were
comparable to those in Group 1. Bleeding time was not prolonged, and
in vitro platelet aggregation was inhibited only when AA was used as
aggregating agent. Systemic blood pressure was not influenced. These
studies suggest that a drug like ticlopidine, which has a broad spectrum
of pharmacological actions on platelets and platelet-cell interactions,
does retard the development of progressive renal injury when nephron
number is reduced. Specific blocking of thromboxane A2 (TxA2)
biological activity does not influence progressive renal disease in rats
with remnant kidney.
In the last ten years many studies have focused on the
process leading to the progression of chronic renal diseases to
end-stage renal failure. It has been found that after an initial
immunological or toxic insult glomerular pressure and flow
increase in remnant nephrons leading to disturbances of gb-
merular microcirculation [1]. This leads to glomerular endothe-
hal cell damage that promotes an abnormal platelet-endothelial
cell and platelet-platelet activation. When platelets become
activated into the glomerular circulation they could release
factors such as platelet-derived growth factor or transforming
growth factor f3, which have been shown in vitro to induce
mesangial cell proliferation [21 and increased generation of
mesangial matrix [3, 4], respectively. If these events also occur
in vivo, they could lead to glomeruboscierosis by progressive
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obliteration of glomerular capillaries. In this context the possi-
bility of retarding renal disease progression by inhibiting blood
coagulation and platelet function has been extensively ex-
plored, particularly in rats with extensive surgical reduction of
renal mass [5—71. The results of a recent study [8] showed that
a TxA2 synthesis inhibitor given to rats with subtotal renal mass
ablation retarded renal disease progression, thus suggesting that
intrarenal platelet activation is a crucial factor in the develop-
ment of glomerulosclerosis. It is of interest that the TxA2
inhibitor in this study, besides inhibiting TxA2 dependent
platelet aggregation, also reduced systemic blood pressure. To
discriminate between the role of platelet aggregation and sys-
temic hypertension in the process of glomerulosclerosis we
recently used low dose ASA [9], with the aim to selectively
suppress platelet TxA2 and TxA2 dependent aggregation with-
out lowering blood pressure. Rats with remnant kidney on low
dose ASA were not protected from proteinuria and gbomerulo-
sclerosis with respect to the vehicle-treated animals. These
experiments would exclude that platelet TxA2 plays an impor-
tant role in renal disease progression. Still, the possibility that it
is indeed important to inhibit platelet activation at glomerular
capillary level in order to retard glomerulosclerosis was not
ruled out by low dose ASA experiments.
TxA2, however, is just one of the many factors potentially
released by activated platelets that may interfere with the
process of progressive renal function deterioration in remnant
kidney [10]. Possibly a molecule inhibiting a wide spectrum of
platelet reactions would be more effective than a selective TxA2
antagonist. In the present study we used ticlopidine—an anti-
platelet agent which unselectively inhibits several stimuli lead-
ing to platelet activation [11, l2]—in comparison to a TxA2
receptor antagonist in a remnant kidney model and evaluated
the degree of protection on renal disease progression.
The novelty of ticlopidine in comparison with the available
platelet function inhibitory drugs mainly lies in its broad spec-
trum of pharmacological actions on platelets and platelet-cell
interactions. Thus, besides blocking arachidonic acid (AA)
induced aggregation, ticlopidine also blocks a number of stimuli
which induce platelet aggregation ex vivo, including ADP,
collagen, epinephrine, ristocetin and PAF acether [13, 14]. In
vivo ticlopidine prolongs bleeding time in man and laboratory
animals [15], causes red cell deformability and decreases blood
viscosity [16]. Thus it appears to act in a complex way on the
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various mechanisms that lead to platelet activation and throm-
bus formation.
The mechanism(s) by which ticlopidine prevents platelets and
platelet-endothelial cell interaction have not been fully clarified.
An interesting possibility is that ticlopidine interferes with the
exposure of fibrinogen receptors on platelets [17]. This process
is independent of TxA2 formation since fibrinogen binding to
platelets is virtually completely prevented by a dose of ticlopi-
dine which does not reduce platelet TxA2 [17, 181.
Methods
Experimental design
Sixty Sprague-Dawley, CD-COBS male rats (Charles River
Italia s.p.a., Calco, Italy) weighing 350 to 375 g at the start of
the experiment were used. Animals were fed standard rat chow
(Altromin, Rieper, Vandoies, Italy) and had free access to tap
water. Forty-five rats underwent right nephrectomy and infarc-
tion of approximately five-sixths of the left kidney by ligation of
two or three extrarenal branches of the main renal artery
according to the method of Olson [7] under ether anesthesia.
Ten days after renal ablation 40 rats survived and were divided
as follows: Group 1, 14 rats given distilled water (vehicle) by
gavage for 50 days; Group 2, 12 rats given ticlopidine (Midy
s.p.a., Milano, Italy) by gavage in aqueous solution at the daily
dose of 150 mg/kg for 50 days; Group 3, 14 rats which were
given the thromboxane receptor antagonist, GR 32191 (Glaxo,
Greenford, UK) by gavage in aqueous solution at the dose of 3
mg/kg b.i,d. for 50 days. Fifteen additional rats underwent sham
operation: laparotomy and manipulation of renal pedicles but
no destruction of renal tissue. Ten days after the sham proce-
dure rats were subdivided as follows: Group 4, five rats which
served as controls and were given distilled water (vehicle) by
gavage for 50 days; Group 5, five rats which were given
ticlopidine (150 mg/kg) by gavage for 50 days; Group 6, five rats
which were given GR 32191 (3 mg/kg b.i.d.) by gavage for 50
days.
The dose of ticlopidine was chosen on the basis of previous
reports in rats showing the efficacy of this drug as an inhibitor
of platelet functions [19—22]. The GR 32191 administration
schedule was established on the basis of previous observations
of a favorable effect of the compound on renal function deteri-
oration in kidney transplanted rats given cyclosporin A [23].
Moreover, we have done an ad hoc study to establish whether
this dose of GR 32191 was effective in antagonizing the biolog-
ical activity of a stable TxA2 mimetic, U466l9 (Cayman Chem-
ical Co. Inc., Ann Arbor, Michigan, USA) in rats with renal
mass reduction. Experiments were performed 40 days after
surgical ablation when urinary TXB2 excretion was previously
found to be significantly increased [9]. Anesthetized animals
(450 to 470 g body wt) underwent renal clearance studies as
follows. After surgery and a 50-minute equilibration period, two
consecutive, 20-minute basal clearance periods were per-
formed. Then the intravenous infusion of U466l9 at the dose of
0.2 g!kgImin (N = 3) for 60 minutes was started. Three
consecutive, 20-minute urine collections with blood samples
obtained at the mid-point of each period were made for calcu-
lation of whole kidney inulin and p-aminohippuric acid (PAH)
clearances, as markers of glomerular filtration rate (GFR) and
renal plasma flow (RPF), respectively. The intravenous infusion
of U46619 significantly reduced GFR and RPF as compared to
pre-infusion basal values (GFR: 0.20 0.04 vs. 0.39 0.06
ml/minIlOO g, P < 0.05; RPF: 0.67 0.15 vs. 1.06 0.12
ml/min/lOO g, P < 0.01). In another group (N = 3) the
experimental design was the same as above, except that the
animals were given GR 32191 by gavage at the dose of 3 mg/kg
b.i.d. starting the day before the clearance study. Infusion of
U466l9 started three hours after the last dose of GR 32191 was
administered. Pre-treatment with GR 32191 prevented the renal
function deterioration induced by U466l9 infusion (GFR, pre-
infusion: 0.37 0.05 ml/minIlOO g, post-infusion: 0.39 0.06
ml/min/l00 g; RPF, pre-infusion: 1.11 0.22 ml/min/100 g,
post-infusion: 0.99 0.11 ml/min/l00 g). When similar experi-
ments were performed in normal rats, again pre-treatment with
GR 32191 (3 mg/kg b.i.d.) completely prevented the renal
function deterioration induced by U466l9 (data not shown).
By the end of the experimental period (60 days after surgery)
four animals in Group 3 had died. However this event seems
more likely related to the natural history of the disease rather
than to a direct toxic effect of the drug as indicated by
toxicological studies in chronically treated rats (unpublished
observations).
In order to verify that the chronic treatment with ticlopidine
or GR 32191 did inhibit platelet function, blood for platelet
aggregation studies was collected from four rats from each
group before scheduled death (60 days after surgery). In all
groups of rats, bleeding time, hematocrit and serum creatinine
were measured at the same period. Twenty-four hour urines
were collected from all animals in metabolic cages on days 0,
10, 20, 40 and 60 after the surgical procedure for urinary protein
excretion measurement. Urinary samples for thromboxane B2
(TxB2) and 6-keto-PGF1, determination were collected from all
groups of rats at the end of the experimental period. Renal
clearance studies were carried out and blood pressure was
measured in four rats from each group before death, that is, 60
days after surgery. Renal tissue specimens were obtained from
all animals at the end of the study and processed for light
microscopy.
To clarify whether lowering systemic blood pressure in
addition to inhibit platelet function might be crucial in prevent-
ing the renal disease progression in rats with reduced renal
mass, additional experiments were performed in 16 rats with
renal mass ablation given a new non-selective /3-blocker, terta-
tolol (Institut de Recherches Internationales Servier, Neuilly-
sur Seine, France) [24] (N = 8 rats) or saline (vehicle; N = 8
rats). Ten days after the above-described ablative procedure,
rats were anesthetized with ether, the ventral neck was shaved
and cleaned, and an incision was made to the left side of the
midline. The extrarenal jugular vein was exposed and a PE-lO
polyethylene catheter (Clay-Adams, Parsippany, New Jersey,
USA) inserted to allow i.v. drug or vehicle infusion. The
catheter was connected through a PE-60 tubing to a filled
ALZETTM osmotic minipump (type 2ML4; delivery rate 2.5
pl/hour; ALZA, Palo Alto, California, USA). The whole system
was air-free. The minipump was inserted into a pocket made in
the side of the neck. Skin incision was closed with two or three
wound clips. After four weeks the minipump was replaced with
a new one containing tertatolol or vehicle. Tertatolol was
delivered at the rate of 1 mg/kg/day for 50 days. Twenty-four
hour urines were collected from all rats in metabolic cages on
936 Zoja et a!: Ticlopidine in rats with remnant kidney
day 60 after the surgical procedure for urinary protein excretion
measurement. Renal clearance studies were performed and
blood pressure measured in all rats before the sacrifice, which
was 60 days after surgery. Renal tissue specimens were ob-
tained from all animals at the end of the study and processed for
light microscopy.
Platelet aggregation experiments
Blood for platelet aggregation studies was drawn by cardiac
venipuncture in 3.1% trisodium citrate (1:10). Platelet rich
plasma (PRP) was obtained by centrifugation at 200 x g for 15
minutes at room temperature; after PRP was removed the
residual blood sample was centrifuged at 2000 x g for 10
minutes to obtain platelet-poor plasma (PPP). The PRP platelet
count was adjusted to 5 x l0 platelets/id with autologous PPP.
Platelet aggregation was induced by ADP (Sigma Chemical Co.,
St. Louis, Missouri, USA) and arachidonic acid (AA) (Sigma),
as previously described [25]. Threshold aggregating concentra-
tion was defined as the lowest concentration of aggregating
agent which induced irreversible platelet aggregation starting
within three minutes after the addition of the aggregating agents
to PRP.
Bleeding time
Bleeding time was determined as previously described [26].
Non-anesthetized rats were placed in a plastic cylinder with
several openings, from one of which the rat's tail emerged.
Bleeding time was measured using a standardized Simplate II
device (General Diagnostic, Milan, Italy). The device was
applied longitudinally on the dorsal part of the tail vein between
6 and 9 cm from the tip, taking care to avoid large veins. The
tails were left in the air and the animals were maintained at
room temperature. Bleeding time was measured and expressed
in seconds from the moment the tail was incised until bleeding
stopped completely (no rebleeding within 30 seconds).
Hematocrit
Hematocrit was measured by a standard laboratory proce-
dure.
Serum creatinine
Serum was obtained by leaving 1 ml portions of native blood,
collected from the tail vein of anesthetized animals, at 37°C for
30 minutes. The prepared sera were frozen and kept at —20°C
until assayed. Creatinine was measured by the alkaline picrate
method [27].
Urinary protein excretion
Proteinuria was determined by the modified Coomassie blue
G dye-binding assay for proteins [28] using bovine serum
albumin as standard.
Urine extraction
Because urine contains a complex mixture of AA metabolites
besides factors that may interfere with any antigen-antibody
reaction, urinary samples were extracted before radioimmuno-
assay (RIA) as previously described [29]. Briefly, after the
addition of 6,000 dpm 3H-TxB2 or 3H-6-keto-PGF1, (Amer-
sham International, Buckinghamshire, UK, 113 Cilmmol or 130
Ci/mmol, respectively) for the estimation of recovery (60 to
75%), urine (3 ml) was acidified to pH 3.5 and passed through a
disposable (C 18) column (Sep-pak, Millipore, Milford, Massa-
chusetts, USA) already activated with methanol and water. The
column was subsequently eluted with water, n-hexane and
ethylacetate. The latter fraction was dried on a rotary evapora-
tor at 37°C. Silicic acid column chromatography was performed
as described previously [30]. Briefly, silicic acid was dissolved
in benzene ethyl:acetate (60:40, solvent A) and added to a small
glass column, which was washed with benzene:ethylacetate:
methanol (60:40:20, solvent B) and solvent A. For 6-keto-
PGFIa solvent C (benzene/ethylacetate/methanol 60:40:30) in-
stead of solvent B was used. The extracted residue was
resuspended in 0.2 ml of benzene:ethylacetate:methanol (60:
40:10 solvent D) and 0.8 ml of solvent A and applied to the
silicic acid column. Prostaglandin (PG) fractions were eluted
with solvent A and subsequently with solvent B for TxB2 or
solvent C for 6-keto-PGF1. The latter elution volume was dried
at 37°C on a rotary evaporator, redissolved in phosphate buffer
and frozen at —20°C until assay.
Radioimmunoassay
Extracted urinary samples were diluted 1:5 to 1:30 for TxB2,
the stable breakdown product of TxA2, 1:50 to 1:100 for
6-keto-PGF1a, the stable hydrolysis product of prostacyclin
(PGI2). RIA was performed as described previously [29]. Re-
sults were expressed as nglday. The smallest concentration that
could be measured with 95% confidence was 2 pg/mi for both
antisera. Cross-reactivity at 50% displacement of other arachi-
donate metabolites was previously reported [29]. Inter-assay
and intra-assay variability, evaluated by assays of several
urinary samples, averaged respectively 4% and 3%, over a
range of concentrations from 1 to 100 pg/mI.
RIA measurements were validated by several independent
criteria: dilution and recovery studies, comparisons of multiple
antisera and characterization of the pattern of distribution of the
extracted thromboxane and 6-keto-PGF ia-like immunoreactiv-
ity on thin layer chromatography, and comparison with gas
chromatographic-mass spectrometric determinations.
Renal clearance studies
The rats were anesthetized by intraperitoneal injection of
thiopental sodium (50 mg/kg body weight). Surgical preparation
consisted of tracheostomy, cannulation of femoral artery and
vein and placement of a polyethylene tube (PE-50) into the
bladder through a small suprapubic incision for collection of
urine into preweighed vessels. Throughout the experiment
arterial blood pressure was continuously monitored directly
from the femoral artery by a polyethylene catheter (PE-50)
connected to a Statham pressure transducer and a carrier
amplifier (Battaglia Rangoni, Bologna, Italy). Saline solution,
1.4 ml containing 5% inulin and 0.25% p-aminohippuric acid
(PAH), was infused into the femoral vein over two minutes as a
priming dose, followed by a constant infusion of a maintenance
saline solution containing 1.5% inulin and 0.05% PAH at a rate
of 2 mI/hr. A 50-minute equilibration period was allowed after
starting infusion in order to attain constant plasma levels of
inulin and PAH. Three clearance periods of 30 minutes each
were allowed. At the midpoint of each period, 100 d blood
samples were obtained from the femoral artery and plasma was
separated by centrifugation. Urine samples were collected from
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Table 1. Effect of ticlopidine and GR 32191 on body weight,
hematocnt and serum creatinine in rats with reduction of renal mass
(RMR) or sham-operated rats at the end of the experimental period
Serum
Body wt
g
Hematocrit
%
creatinine
mg/dl
RMR + vehicle 497 47 45.6 3.3" 1.32 0.32"
RMR + ticlopidine 474 53 50.1 44b 0.94 0,20e,f
RMR + GR 32191 480 48 44.6 9,QC 1.27 053g
Sham + vehicle 534 69 51.6 1.5 0.71 0.05
Sham + ticlopidine 533 53 52.0 2.1 0.68 0.13
Sham + GR 32191 522 58 51.6 1.1 0,69 0.14
Values are mean SD.
a P < 0.05 vs. all sham-operated rat groupsbP < 0.05 vs. RMR + vehicle and RMR + GR 32191
P < 0.05 vs. all sham-operated rat groups
"P < 0.01 vs. all sham-operated rat groups
P < 0.05 vs. RMR + GR 32191
P < 0.01 vs. RMR + vehicle
P < 0.01 vs. all sham-operated rat groups
the bladder in preweighed vessels. Plasma and urine inulin and
PAH were determined by methods previously described [31,
32], modified for microliter samples.
Histological studies
Light microscopy. Fragments of kidneys were fixed for 12
hours in Dubosq-Brazil, dehydrated in alcohol and embedded in
paraffin. Sections (3 ) were stained with hematoxylin and
eosin, Masson's trichrome, periodic acid-Schiff's reagent (PAS-
stain) and Wilder's reticulin. Sections including superficial and
juxtamedullary glomeruli were evaluated. For each animal at
least 150 glomeruli were examined and the percentage of
glomeruli presenting focal or global glomeruloscierosis was
determined. Tubular changes (atrophy, casts, dilatation) and
interstitial fibrosis and inflammation were graded from 0 to 4+
(0 = no changes; 1+ = changes affecting less than 25% of the
sample; 2+ = changes affecting 25 to 50% of the sample; 3+
changes affecting 50 to 75% of the sample; 4+ = changes
affecting 75 to 100% of sample). All renal biopsies were ana-
lyzed by the same pathologist, unaware of the nature of the
experimental groups.
Statistical analysis
All results were expressed as mean SD. Except for protein-
uria and histological score, data were subjected to one-way
analysis of variance, Significance of differences between indi-
vidual group means was established using Duncan's multiple-
range test. Urinary protein excretion data were evaluated by
two-way analysis of variance using Tukey-Cicchetti' s test for
specific multiple comparisons. Statistical analysis of histologi-
cal data was done by the Kruskal-Wallis test with Ryan's
procedure and Spearman rank correlation test. Data of all the
parameters considered for the additional groups of rats given
tertatolol and vehicle were analyzed by the unpaired Student's
t-test. Statistical significance level was defined as P < 0.05.
Results
Body weight
Final body weights for all the experimental animals are
shown in Table 1. Body weights of all groups of rats with renal
Table 2. ADP and AA threshold aggregating concentrations of
platelet rich plasma from rats with reduction of renal mass (RMR) or
sham-operated rats at the end of the experimental period
ADP
LM
AA
mM
RMR + vehicle 12.5 3.4 1.6 0.3
RMR + ticlopidine 32.5 5.3" >2
RMR + GR 32191 12 3.3 >2
Sham + vehicle 9.5 3.4 0.7 0.3
Sham + ticlopidine 31.5 6.6" >2
Sham+GR32l9l 11±2 >2
Values are mean su.
a P < 0.01 vs. RMR + vehicle and RMR + GR 32191
b P < 0.01 vs. sham + vehicle and sham + GR 32191
mass reduction tended to be lower than those of sham-operated
animals, although a statistical significance was not reached.
Effect of ticlopidine and GR 32191 on platelet aggregation in
rats with reduced renal mass
In order to verify whether the doses of ticlopidine and GR
32191 employed were effective in inhibiting platelet function,
we studied ADP and AA-induced platelet aggregation in four
rats from each experimental group 60 days after surgery. Mean
threshold aggregating concentrations of ADP in rats with re-
duced renal mass and sham-operated rats given ticlopidine were
significantly (P < 0.01) higher than in rats receiving vehicle or
GR 32191 (Table 2). GR 32191 did not influence ADP-induced
platelet aggregation as previously reported in humans [33].
Concentrations of AA up to 2 m were unable to induce
aggregation in PRP from rats with reduced renal mass and
sham-operated rats given either ticlopidine or GR 32191.
Effect of ticlopidine and GR 32191 on bleeding time in rats
with reduced renal mass
Since ticlopidine has been reported to prolong bleeding time
in humans [15], the effects of both treatments on platelet-
platelet and platelet-vessel wall interactions were assessed by a
global test of primary hemostasis such as the skin bleeding time.
Bleeding time was measured at the end of the experimental
period. In agreement with a recent report [26], bleeding times in
rats with reduced renal mass given vehicle were significantly (P
<0.01) longer than in control sham-operated rats (270 28 vs.
95 9 seconds; Fig. 1). Ticlopidine further prolonged the
bleeding time of rats with renal mass reduction and these times
became significantly (P < 0.01) longer than those of rats with
renal mass reduction given vehicle or GR 32191 (ticlopidine, 328
38; vehicle 270 28; GR 32191, 253 31 seconds). As
expected, in sham-operated rats treated with ticlopidine, bleed-
ing times were significantly (P < 0.01) longer than in the other
two sham-operated groups (ticlopidine, 217 41; vehicle, 95
9; GR 32191, 122 33 seconds). GR 32191 had no significant
effect on bleeding time in rats with reduced renal mass. In
sham-operated animals bleeding time tended to be prolonged in
comparison with sham-operated rats given vehicle, although a
statistical significance was not reached. The fact that in animals
with reduced renal mass treated with GR 32191 bleeding time
was not further increased with respect to animals with renal
mass reduction given the vehicle alone could possibly be
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Sham operation
Fig. 1. Effect of ticlopidine and GR 32191 on bleeding time in rats with
renal mass reduction (RMR) or sham-operated rats at the end of the
experimental period (60 days after surgery). Symbols are: () vehicle;
(U) ticlopidine; (D) GR 32191. Values are mean SD. * P < 0.01 vs.
sham ÷ vehicle and sham + GR 32191; °P < 0.01 vs. RMR + vehicle
and RMR + GR 32191; + P < 0.01 vs. sham + vehicle and sham + GR
32191; X P < 0.01 vs. sham + vehicle and sham + GR 32191.
explained by the fact that reduction of renal mass 'per Se' leads
to a marked prolongation of bleeding time (a likely result of the
platelet function defect of uremia) so that the pure effect of GR
32191 in this condition could not be established.
Effect of ticlopidine and GR 32191 on hematocrit in rats with
reduced renal mass
Table 1 Sets out the hematocrits for all groups of rats with
reduction of renal mass and sham-operated rats at the end of the
experimental period. Hematocrits were significantly (P < 0.05)
lower in rats with renal mass reduction given vehicle than in
sham-operated controls. Ticlopidine protected rats with re-
duced renal mass from the drop in hematocrit to the extent that
their hematocrits were significantly (P < 0.05) higher than in
rats with renal mass reduction given vehicle alone, and compa-
rable to those of all sham-operated rat groups. The thrombox-
ane receptor antagonist GR 32191 given to rats with renal mass
reduction did not change hematocrit compared with rats with
renal mass ablation given vehicle. These values were signifi-
cantly lower (P < 0.05) than those of sham-operated rat groups.
Effect of ticlopidine and GR 32191 on renal function in rats
with reduced renal mass
To establish whether chronic treatment with ticlopidine or
GR 32191 retarded the progression of renal disease in rats with
reduced renal mass, we measured serum creatinine and renal
inulin and PAH clearances in all the experimental groups.
Animals with renal mass reduction given vehicle showed a
significant (P < 0.01) increase in serum creatinine compared
with sham-operated control rats (Table 1). Serum creatinine
was significantly lower in rats with renal mass ablation treated
with ticlopidine than in those with renal mass reduction given
either vehicle (P < 0.01) or GR 32191 (P < 0.05). By contrast
(Table 1), serum creatinine was similar in rats with renal mass
ablation given GR 32191 and those given vehicle. In sham-
operated animals serum creatinine concentrations were not
modified by either ticlopidine or GR 32191.
Since serum creatinine may not be an absolute indicator of
Fig. 2. Effect of ticlopidine and GR 32191 on glomerular filtration rate
(GFR) (A) and renal plasma flow (RPF) (B) in rats with renal mass
reduction (RMR) or sham-operated rats at the end of the experimental
period. Symbols are:()vehicle; (U) ticlopidine; () GR 32191. Values
are mean SD, N = 4. * P < 0.01 vs. all sham-operated groups; °P <
0.05 vs. RMR + vehicle; + P < 0.01 vs. RMR + GR 32191; X P < 0.01
vs. all sham-operated rat groups; ** P < 0.01 vs. RMR + vehicle and
RMR + GR 32191.
glomerular filtration rate (GFR) we also measured GFR in four
rats from each group using inulin clearance. As shown in Figure
2A, in animals with renal mass reduction given vehicle, GFR
was significantly (P < 0.01) lower in sham-operated control rats
(0.27 0.08 vs. 0.80 0.06 mLlmin/l00 g). Ticlopidine treat-
ment ameliorated renal function of rats with renal mass reduc-
tion, as indicated by a significant increase in GFR in compari-
son with rats with renal mass ablation given vehicle (P < 0.05)
or GR 32191 (P < 0.01) (ticlopidine, 0.42 0.09; vehicle, 0.27
0.08; GR 32191, 0.16 0.05 mllmin/100 g). In rats with renal
mass ablation treated with GR 32191 and in those given vehicle
GFR was not significantly different. No significant differences
in GFR were observed in sham-operated rats after treatment
with ticlopidine, GR 32191 or vehicle (ticlopidine, 0.80 0.07;
GR 32191, 0.78 0.11; vehicle, 0.80 0.06 mllmin/l00 g).
Renal plasma flow (RPF) measured as PAH clearance was
significantly (P < 0.01) lower in rats with reduced renal mass
given vehicle than in sham-operated controls (0.58 0.15 vs.
2.18 0.20 mllmin/lOO g; Fig. 2B). RPF of rats with ablation of
renal mass treated with ticlopidine was double (P < 0.01) that in
rats with renal mass reduction given vehicle or GR 32191
(ticlopidine, 1.36 0.24; vehicle, 0.58 0.15; GR 32191, 0.49
0.21 mllmin/lOO g). As shown in Figure 2B, RPF in rats with
renal mass ablation receiving GR 32191 or vehicle was the
same. In sham-operated animals RPF was not affected by either
ticlopidine or GR 32191 treatment (ticlopidine, 2.19 0.20; GR
32191, 2.22 0.18 ml/min/100 g).
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RMR + vehicle 194.2 18.2°
RMR + ticlopidine 162.5 64b
RMR + GR 32191 179.5 15.4C
Sham + vehicle 132.7 5.9
Sham + ticlopidine 126.2 9.8
Sham + GR 32191 141.2 8.5
Effect of ticlopidine and GR 32191 on blood pressure in rats
with reduced renal mass
Arterial blood pressure in anesthetized rats that underwent
clearance studies is shown in Table 3. Blood pressure was
significantly (P < 0.01) higher in rats with renal mass reduction
given vehicle than in sham-operated controls. Ticlopidine sig-
nificantly (P < 0.01) lowered blood pressure of rats with renal
mass ablation in comparison with rats with reduced renal mass
given vehicle alone. Neither GR 32191 nor vehicle had any
effect on blood pressure in rats with remnant kidney. In
sham-operated rats blood pressure was not influenced by treat-
ment with either ticlopidine or GR 32191.
Effect of ticlopidine and GR 32191 on proteinuria in rats with
reduced renal mass
Figure 3 shows the time course of urinary protein excretion.
Animals with renal mass reduction given vehicle developed
proteinuria by 20 days after surgery. Proteinuria on day 40 was
significantly (P < 0.01) different from basal level (137.60
52.85 vs. 23.52 7.9 mg/day) and the difference persisted for
several days. At the end of the study proteinuria was 222.22
133.79 mg/day (P < 0.01 vs. basal). In animals with renal mass
reduction given ticlopidine urinary protein excretion on days 40
and 60 after surgery was significantly (P < 0.01) lower than in
rats with renal mass reduction given vehicle or GR 32191 (day
40: ticlopidine, 51.71 32.19; vehicle, 137.60 52.85; GR
32191, 190.05 114.83 mg/day. Day 60: ticlopidine, 89.04
34.07; vehicle: 222.22 133.79; GR 32191, 238.21 132.79
mg/day). GR 32191 did not influence the time course of urinary
protein excretion of rats with renal mass ablation (Fig. 3). No
sham-operated animals developed proteinuria. At the end of the
study (60 days after surgery) values were: ticlopidine, 24.83
9.68; vehicle, 25.06 8.81; GR 32191, 35.79 17.86 mg/day.
Effect of ticlopidine and GR 32191 on urinary excretion of
TxB2 and 6-keto-PGF, in rats with reduced renal mass
The effect of ticlopidine and GR 32191 on urinary excretion of
TxB2 and 6-keto-PGF1 was studied in all the experimental
groups at the end of the study (Table 4). As previously reported
[81, rats with renal mass reduction given vehicle had signifi-
cantly (P < 0.01) higher urinary excretion of TxB2 than sham-
operated controls. Neither ticlopidine nor GR 32191 treatment
r,-i râ'1 r7;:L1 r1i
Fig. 3. Time course of urinary protein excretion in rats with renal mass
reduction (A) or (B) sham-operated rats given vehicle (a), ticlopidine(•) or GR 32191. (D) Values are mean SD. * P < 0.01 vs.
corresponding day 0; X P < 0.01 vs. RMR + vehicle and RMR + GR
32191 at the corresponding time; P < 0.01 vs. corresponding day 0.
Table 4. Effect of ticlopidine and GR 32191 on urinary excretion rate
of TxB2 and 6-keto-PGF1 in rats with reduction of renal mass
(RMR) or sham-operated rats at the end of the experimental period
TxB2
nglday
6-keto-PGF1
ng/day
RMR + vehicle 19.56 4.90° 28.76 4.26
RMR + ticlopidine 20.24 5.06a 30.11 7.06
RMR + GR 32191 21.80 743k 34.03 6.32
Sham + vehicle 10.05 1.67 30.21 5.02
Sham + ticlopidine 10.62 3.29 29.01 5.76
Sham + GR 32191 9.42 2.71 33.41 8.66
affected urinary TxB2 excretion in rats with renal mass ablation.
Similarly, in sham-operated rats urinary excretion of TxB2 was
not modified by ticlopidine or GR 32191. Urinary excretion of
6-keto-PGF1 in rats with remnant kidney given vehicle was not
different from that in sham-operated control animals (Table 4).
Neither ticlopidine nor GR 32191 modified urinary excretion of
6-keto-PGF1 in rats with renal mass reduction or in sham-
operated rats.
Pathological studies
Glomerular, tubular, interstitial and vascular changes are
quantified in Table 5. Rats with reduced renal mass given
vehicle showed irregularly distributed glomerular sclerotic
changes. Lesions were characterized by segmental areas of
Table 3. Effect of ticlopidine and GR 32191 on blood pressure in rats
with reduction of renal mass (RMR) or sham-operated rats at the end
of the experimental period
A Renal mass reduction
Blood
pressure
mm Hg
*
+
Values are mean SD.
a P < 0.01 vs. all sham-operated rat groupsb p < 0.01 vs. RMR + vehicle
P < 0.01 vs. all sham-operated rat groups.
*
E
a
C
a00
41
0)
Co
C
Co
00
0 10
B Sham operation
400
20 40 60
300
200
100•
0
Time, days
Values are mean SD.
a p < 0.01 vs. all sham-operated rat groups
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Table 5. Pathological changes in rats with renal mass reduction
(RMR) chronically given vehicle, ticlopidine or GR 32191
Group
Percentage of
glomeruli
with sclerotic
changes
Tubular
casts
Interstitial
changes
Vascular
changes •
RMR + vehicle 22.9 1.21 0.89 0,96
N = 14 (2—50.9) (0.5—2) (0.5—1.5) (0—2)
RMR + ticlopidine 6.9a o.Soa Q•4()a 045b
N = 12 (1—24) (0—1) (0—1) (0—I)
RMR + GR 32191 20.4 1.33 1.15 1.1
N = 10 (9—31) (0.5—2) (0.5—2) (0.5—2)
Values are mean percentages and mean
ranges.
a P < 0.01 vs. RMR + GR 32191
b P < 0.01 vs. RMR + GR 32191
scores; in parenthesis,
sclerosis and hyalinosis with capillary collapsing and adhesion
to Bowman's capsule. Signs of extracapillary proliferation were
present in some glomeruli. Occasional glomeruli underwent
global obsolescence. In the glomeruli spared by sclerotic
changes the mesangial matrix was moderately expanded and the
cytoplasm of podocytes showed pronounced swelling. Hyper-
trophy and a moderate number of proteinaceous casts were
seen in the distal and collecting tubules. Interstitial inflamma-
tion and fibrosis were patchy and not particularly severe. Most
animals showed moderate arterial and arteriolar narrowing.
In rats with reduction of renal mass given ticlopidine glomer-
ular sclerosis and hyalinosis were significantly (P < 0.01) less
diffuse and severe than in rats with reduced renal mass given
vehicle. Tubular and interstitial changes were mild. Few ani-
mals showed signs of arterial and arteriolar narrowing. In rats
with reduction of renal mass given GR 32191 the pathological
changes were of virtually the same severity as in animals with
reduction of renal mass given vehicle. In some animals the
arterioles showed pronounced narrowing of the lumens. A
significant correlation between urinary protein excretion and
percent of glomeruli with focal segmental glomerulosclerosis
was found in all three groups (Group 1: r = 0.77, P < 0.001;
Group 2: r = 0.70, P < 0.01; Group 3: r = 0.80, P < 0.05).
Sham-operated animals treated with ticlopidine or GR 32191 did
not present any significant glomerular, tubular, interstitial or
vascular damage.
Effect of tertatolol treatment in rats with reduced renal mass
Table 6 summarizes the mean values for hematocrit, GFR,
RPF, arterial blood pressure and proteinuria for rats with
reduced renal mass studied after 50 days treatment with vehicle
or tertatolol. No significant difference in hematocrit values
between the two groups was found. In rats with renal mass
ablation treated with tertatolol, GFR was not significantly
different from that of animals given vehicle. Similarly, RPF was
not influenced by tertatolol treatment. Blood pressure was
significantly (P < 0.01) decreased in rats receiving tertatolol in
comparison with vehicle-treated animals. Proteinuria was not
affected by tertatolol treatment. In rats with renal mass reduc-
tion treated with tertatolol the degree of glomerular damage was
not different from that of rats with renal mass reduction
receiving the vehicle. The mean percentage of glomeruli af-
fected by sclerosis and hyalinosis was: tertatolol, 23.5 (range: 3
to 48); vehicle, 22.2 (range: 7 to 37). Tubular, interstitial and
vascular changes were similar in the two groups of rats. Mean
score of tubular casts was: tertatolol, 1.25 (range: 0.5 to 2);
vehicle, 1.31 (range: 0.5 to 2). Mean score of interstitial changes
was: tertatolol, 1.0 (range: 0.5 to 1.5); vehicle, 1.12 (range: 0.5
to 2). Mean score of vascular changes was: tertatolol, 0.93
(range: 0 to 2); vehicle, 1.0 (range: 0 to 2).
Discussion
The present study was designed to assess whether platelet
function inhibition retards the progressive renal disease that
follows extensive surgical ablation of renal mass. Rats with
subtotal nephrectomy received chronic treatment with ticlopi-
dine, or with GR 32191, a thromboxane receptor antagonist that
rather selectively affects platelet function by inhibiting the
biological activity of TxA2 [34—36]. The results showed that
ticlopidine, but not the selective TxA2 receptor block, favor-
ably influenced the progression of the disease.
In animals given ticlopidine in particular renal function
improved as indicated by a significant increase in GFR and RPF
in comparison with rats receiving the vehicle alone. Urinary
protein excretion was lower in animals given ticlopidine than in
the corresponding controls. The difference was already signifi-
cant at day 40 and remained so until day 60 when the animals
were killed. Analysis of histopathological changes indicated
that the degree of glomerulosclerosis and tubulointerstitial
damage was significantly lower than in animals with reduction
of renal mass given vehicle.
Rats with renal mass ablation given the selective thrombox-
ane antagonist GR 32191, at a dose which completely blocks
decrease in GFR and RPF induced by a stable TxA2 mimetic in
vivo, were not protected from the progressive deterioration of
renal function compared to nephrectomized animals given the
vehicle, nor was urinary protein excretion different in the two
groups of rats at the various intervals considered. Analysis of
histopathological changes showed that the degree of glomeru-
losclerosis and tubulointerstitial damage in animals given GR
32191 was comparable to that of the corresponding controls.
Unlike ticlopidine, the pharmacological activity of GR 32191 is
more selective in that it inhibits platelet aggregation induced by
TxA2, U 46619, prostaglandin H2 and AA, but does not affect
the primary phase of aggregation produced by adrenalin, 5-
hydroxytryptamine or ADP [33, 361.
Thus comparative analysis of ticlopidine and GR 32191's
effects on progression of the disease in the remnant kidney
indicates that TxA2 is not of significant pathophysiological
importance in this model. The fact that ticlopidine, which
inhibits a wide spectrum of platelet reactions, retards the
progression of the disease in the remnant kidney model is
consistent with the possibility that intraglomerular thrombosis
contributes to the development of glomerulosclerosis in animals
and humans after the loss of a critical number of nephron units
[61.
The exact nature of the factors involved in this process and
the sequence of the various events implicated remain ill-
defined. It has been postulated that mediators of platelet or
endothelial cell origin induce macrophage accumulation; these
in turn are activated and either express membrane procoagulant
activity or release procoagulant factors [37]. The fact that the
early event in this process involves more than one pathway of
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Table 6. Effect of tertatolol on hematocrit, GFR, RPF, blood pressure and proteinuria in rats
of the experimental period
with reduction of renal mass (RMR) at the end
.Hematocrit
%
GRF RPF Blood
pressure
mm Hg
Proteinuna
mg/daym!/min/100 g
RMR + vehicle
RMR + tertatolol
44.7 4.1
43.1 5.8
0.26 0.06 0.66 0.10
0.29 0.06 0.72 0.15
191.6 7.8
126.3 9.Oa
203.42 100.08
197.45 94.55
Values are mean SD.
a P < 0.01 vs. RMR + vehicle
platelet activation and platelet-endothelial cell interaction
would explain the different results with ticlopidine and GR
32191 in the present investigation.
Failure of GR 32191 to retard progression of the disease in the
remnant kidney model is consistent with previous reports that
low-dose oral ASA—which also selectively suppresses platelet
thromboxane—does not protect rats from the development of
progressive disease after extensive ablation of renal mass [9].
Our findings with GR 32191 appear to contrast with those of
Purkerson et al [81 who found that a selective thromboxane
synthase inhibitor favorably influenced the progression of renal
disease in the same model. This apparent difference between
our GR 32191 and ASA results and those reported by Purker-
son's group [8] using the thromboxane synthase inhibitor OKY
1581, might be reconciled if one considers that OKY 1581 not
only prevents platelet and possibly renal cell TxA2 formation,
but also lowers blood pressure and cardiac index. This was not
observed in nephrectomized animals given either GR 32191 or
low-dose ASA. This interpretation is in keeping with the
findings that systemic hypertension accelerates the progression
of various renal diseases [38—40] and that antihypertensive
therapy prevents further renal function deterioration [41—43].
An intriguing finding of the present investigation is that
ticlopidine, besides inhibiting platelet aggregation and prolong-
ing bleeding time, also lowered blood pressure in rats with
reduction of renal mass. Whether the antiplatelet or the antihy-
pertensive activity of ticlopidine is more important in retarding
progressive nephropathy or whether the two activities to be
effective must be combined, remains a matter of speculation.
Normalization of systemic blood pressure alone with combina-
tion drug therapy [44] leads to only a slight reduction of
glomerular injury in rats with renal mass ablation, unless it is
associated with a parallel reduction of glomerular capillary
hydraulic pressure. Our present finding that tertatolol does not
prevent renal function deterioration in this model despite nor-
malizing the blood pressure, is in agreement with the above
mentioned findings. It has to be pointed out, however, that this
is still an ill defined area of investigation since there have been
other studies which showed that lowering systemic blood
pressure alone protected animals with remnant kidney from
further renal function deterioration [45]. Thus, despite the data
on the use of tertatolol might be taken to indicate that the
protective effect of ticlopidine is not only due to its antihyper-
tensive effect alone, this possibility could not be definitely ruled
out, if one considers all the published literature on this subject.
In conclusion, our present findings may be interpreted as
indicating that non-TxA2-dependent platelet activation and pos-
sibly intraglomerular thrombosis mediate the process of pro-
gressive renal function deterioration which follows extensive
reduction of renal mass in the rat. Since platelet-fibrinogen
binding may be an important step in this process, future
therapeutic strategies aimed at slowing the process of progres-
sive glomerulosclerosis might better be based on drugs that
interfere with platelet-fibrinogen binding rather than on mole-
cules that selectively block TxA2 biological activity. The pos-
sible additional utility of lowering systemic and/or intraglomer-
ular capillary pressure as well as inhibiting platelet function has
also to be further explored by ad hoc studies.
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